Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma

NCT00109863 Phase 2 COMPLETED

RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanoma.

Details

Lead sponsor	University of Wisconsin, Madison
Phase	Phase 2
Status	COMPLETED
Enrolment	14
Start date	2005-05
Completion	2014-02

Conditions

• Melanoma (Skin)

Interventions

• hu14.18-IL2 fusion protein

Primary outcomes

• Objective response rate and duration of response by clinical exam and radiology studies after every 2 courses

Countries

United States